MX2021000813A - Oligómeros de salto de exón para distrofia muscular. - Google Patents
Oligómeros de salto de exón para distrofia muscular.Info
- Publication number
- MX2021000813A MX2021000813A MX2021000813A MX2021000813A MX2021000813A MX 2021000813 A MX2021000813 A MX 2021000813A MX 2021000813 A MX2021000813 A MX 2021000813A MX 2021000813 A MX2021000813 A MX 2021000813A MX 2021000813 A MX2021000813 A MX 2021000813A
- Authority
- MX
- Mexico
- Prior art keywords
- muscular dystrophy
- exon skipping
- oligomers
- sup
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Abstract
La presente invención se refiere a oligómeros antisentido complementarios a un sitio de objetivo seleccionado en el gen de distrofina humana para inducir el salto del exón 2; en varios aspectos, se describen oligómeros antisentido de conformidad con la Fórmula (I): (ver fórmula I) o una sal del mismo farmacéuticamente aceptable, en donde T, Nu, n, y R100 se definen en la presente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862711215P | 2018-07-27 | 2018-07-27 | |
US201962868003P | 2019-06-28 | 2019-06-28 | |
PCT/US2019/043330 WO2020023688A1 (en) | 2018-07-27 | 2019-07-25 | Exon skipping oligomers for muscular dystrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000813A true MX2021000813A (es) | 2021-06-15 |
Family
ID=67770557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021000813A MX2021000813A (es) | 2018-07-27 | 2019-07-25 | Oligómeros de salto de exón para distrofia muscular. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220364084A1 (es) |
EP (1) | EP3830266A1 (es) |
JP (2) | JP2021531009A (es) |
KR (1) | KR20210038581A (es) |
CN (1) | CN112639097A (es) |
AU (1) | AU2019309394A1 (es) |
BR (1) | BR112021001575A2 (es) |
CA (1) | CA3105668A1 (es) |
CL (1) | CL2021000203A1 (es) |
CO (1) | CO2021001886A2 (es) |
IL (1) | IL280299A (es) |
MX (1) | MX2021000813A (es) |
SA (1) | SA521421104B1 (es) |
SG (1) | SG11202012679XA (es) |
TW (1) | TW202020153A (es) |
WO (1) | WO2020023688A1 (es) |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
EP0215942B1 (en) | 1985-03-15 | 1995-07-12 | Antivirals Inc. | Polynucleotide assay reagent and method |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
KR100782896B1 (ko) | 1999-05-04 | 2007-12-06 | 엑시콘 에이/에스 | L-리보-lna 유사체 |
US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
WO2001047496A1 (en) | 1999-12-29 | 2001-07-05 | Mixson A James | Histidine copolymer and methods for using same |
KR20020097241A (ko) * | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
JP4836366B2 (ja) * | 2000-08-25 | 2011-12-14 | 雅文 松尾 | デュシェンヌ型筋ジストロフィー治療剤 |
EP1446412B1 (en) | 2001-09-04 | 2012-03-07 | Exiqon A/S | Novel lna compositions and uses thereof |
KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
KR20030084444A (ko) | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
WO2004043977A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | 2’-fluoro substituted oligomeric compounds and compositions for use in gene modulations |
CA2523672C (en) | 2003-04-29 | 2012-07-17 | Avi Biopharma, Inc. | Compositions for enhancing transport of molecules into cells |
US7211668B2 (en) | 2003-07-28 | 2007-05-01 | Panagene, Inc. | PNA monomer and precursor |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
ES2694726T3 (es) | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Conjugados peptídicos específicos de tejido y métodos |
JP2010533170A (ja) | 2007-07-12 | 2010-10-21 | プロセンサ テクノロジーズ ビー.ブイ. | 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子 |
EP2203173B1 (en) * | 2007-10-26 | 2015-12-23 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
WO2009064471A1 (en) | 2007-11-15 | 2009-05-22 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
KR101881596B1 (ko) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
JP2012523225A (ja) | 2009-04-10 | 2012-10-04 | アソシアシオン・アンスティテュ・ドゥ・ミオロジー | 疾患の処置のためのトリシクロ−dnaアンチセンスオリゴヌクレオチド、組成物及び方法 |
SG177564A1 (en) | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
US8470987B2 (en) | 2009-09-16 | 2013-06-25 | Chiralgen, Ltd. | Protective group for synthesis of RNA and derivative |
CN105838714B (zh) * | 2009-11-12 | 2020-07-17 | 西澳大利亚大学 | 反义分子和治疗疾病的方法 |
WO2011078797A2 (en) * | 2009-12-22 | 2011-06-30 | Singapore Health Services Pte. Ltd | Antisense oligonucleotides and uses threreof |
WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
KR102339196B1 (ko) | 2011-05-05 | 2021-12-15 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
DK2581448T3 (en) | 2011-10-13 | 2015-04-27 | Ass Inst De Myologie | Tricyclo-DNA phosphorothioate |
AU2012345638C1 (en) | 2011-11-30 | 2018-10-18 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
CN104203289B (zh) | 2012-01-27 | 2020-11-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
DE102012101676A1 (de) | 2012-02-29 | 2013-08-29 | Klaus-Dieter Rösler | Verfahren und Vorrichtung zum Bearbeiten von Formularen mit einer Datenverarbeitungsanlage |
EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
AU2015207773B2 (en) | 2014-01-16 | 2021-06-17 | Wave Life Sciences Ltd. | Chiral design |
EP3143141B1 (en) * | 2014-05-16 | 2019-10-02 | Oregon State University | Antisense antibacterial compounds and methods |
CA2957661A1 (en) * | 2014-08-09 | 2016-02-18 | Kevin FLANIGAN | Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene |
WO2016070166A2 (en) | 2014-11-02 | 2016-05-06 | Arcturus Therapeutics, Inc. | Messenger una molecules and uses thereof |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
JP2018530560A (ja) * | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス, インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
CR20180233A (es) | 2015-10-09 | 2018-05-25 | Wave Life Sciences Ltd | Composiciones oligonucleotídicas y sus métodos |
CN107177593B (zh) * | 2016-03-10 | 2020-10-23 | 北京大学 | 利用优化的基因密码子扩展系统通读提前终止密码子疾病中的截短蛋白 |
KR102329187B1 (ko) * | 2016-04-29 | 2021-11-22 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 인간 lmna를 표적화하는 올리고뉴클레오타이드 유사체 |
MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
MA45290A (fr) | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
-
2019
- 2019-07-24 TW TW108126094A patent/TW202020153A/zh unknown
- 2019-07-25 KR KR1020217005045A patent/KR20210038581A/ko unknown
- 2019-07-25 AU AU2019309394A patent/AU2019309394A1/en active Pending
- 2019-07-25 BR BR112021001575-2A patent/BR112021001575A2/pt unknown
- 2019-07-25 CN CN201980050151.9A patent/CN112639097A/zh active Pending
- 2019-07-25 US US17/262,052 patent/US20220364084A1/en not_active Abandoned
- 2019-07-25 CA CA3105668A patent/CA3105668A1/en active Pending
- 2019-07-25 JP JP2021503156A patent/JP2021531009A/ja active Pending
- 2019-07-25 SG SG11202012679XA patent/SG11202012679XA/en unknown
- 2019-07-25 EP EP19759447.6A patent/EP3830266A1/en active Pending
- 2019-07-25 WO PCT/US2019/043330 patent/WO2020023688A1/en unknown
- 2019-07-25 MX MX2021000813A patent/MX2021000813A/es unknown
-
2021
- 2021-01-20 IL IL280299A patent/IL280299A/en unknown
- 2021-01-25 SA SA521421104A patent/SA521421104B1/ar unknown
- 2021-01-26 CL CL2021000203A patent/CL2021000203A1/es unknown
- 2021-02-16 CO CONC2021/0001886A patent/CO2021001886A2/es unknown
-
2023
- 2023-11-27 JP JP2023199853A patent/JP2024023406A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SA521421104B1 (ar) | 2023-03-21 |
CO2021001886A2 (es) | 2021-05-31 |
KR20210038581A (ko) | 2021-04-07 |
AU2019309394A1 (en) | 2021-03-18 |
JP2024023406A (ja) | 2024-02-21 |
CN112639097A (zh) | 2021-04-09 |
US20220364084A1 (en) | 2022-11-17 |
SG11202012679XA (en) | 2021-02-25 |
IL280299A (en) | 2021-03-25 |
JP2021531009A (ja) | 2021-11-18 |
CA3105668A1 (en) | 2020-01-30 |
EP3830266A1 (en) | 2021-06-09 |
WO2020023688A1 (en) | 2020-01-30 |
TW202020153A (zh) | 2020-06-01 |
CL2021000203A1 (es) | 2021-08-13 |
BR112021001575A2 (pt) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019006882A (es) | Conjugados de oligomeros de omision de exon para distrofia muscular. | |
NZ755438A (en) | Exon skipping oligomer conjugates for muscular dystrophy | |
SA519402143B1 (ar) | مترافقات أوليجومرات تخطي الإكسون للحَثَل العَضَلِيّ | |
MX2020003227A (es) | Conjugados de oligomero con omision de exon para la distrofia muscular. | |
WO2019241385A3 (en) | Exon skipping oligomers for muscular dystropy | |
NZ631245A (en) | Exon skipping compositions for treating muscular dystrophy | |
JP2018110601A5 (es) | ||
MX2018016052A (es) | Oligomeros de omision de exon para distrofia muscular. | |
SA515360229B1 (ar) | مثبطات عامل التمايز والنمو 8 | |
MY196809A (en) | (),()-unsaturated amide compound | |
MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
MX2020012645A (es) | Conjugados de oligomeros de salto de exon para la distrofia muscular. | |
CR20200382A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
CY1121945T1 (el) | Προφυλακτικος και θεραπευτικος παραγοντας της ινωσης | |
MX2021006737A (es) | Conjugados de oligómeros de salto de exones para distrofia muscular. | |
MX2022005024A (es) | Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc). | |
TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
MX2020009967A (es) | Compuesto con actividad anticancerigena. | |
MX2021000813A (es) | Oligómeros de salto de exón para distrofia muscular. | |
CR20210181A (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
EA202190336A1 (ru) | Олигомеры для пропуска экзона при мышечной дистрофии | |
MX2019000608A (es) | Derivados de panteteina para tratamiento de trastornos neurologicos. | |
EP4219717A3 (en) | Exon skipping oligomers for muscular dystrophy |